Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 5:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,651 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia Spectrum and Other Psychotic Disorders Clear all
Completed Phase 3 Interventional Results available

Relapse Prevention Study in Patients With Schizophrenia

NCT01291511
View directory record Official record
Conditions
Schizophrenia
Interventions
Iloperidone, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
28
States / cities
Anaheim, California • Bellflower, California • Costa Mesa, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 14, 2026, 5:54 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

FAAH Availability in Psychiatric Disorders: A PET Study

NCT04404712
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Alcohol Use Disorder, Psychosis
Interventions
[11C]MK-3168
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 14, 2026, 5:54 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder

NCT00156715
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Psychotic Disorder, Substance Abuse, Alcohol Abuse
Interventions
Quetiapine
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
4
States / cities
Augusta, Georgia • Lebanon, New Hampshire • Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 14, 2026, 5:54 PM EDT
Completed No phase listed Observational

Effect of Antipsychotics on Appetite Regulation

NCT00903916
View directory record Official record
Conditions
Psychotic Disorders
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 40 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Oct 14, 2026, 5:54 PM EDT
Completed Not applicable Interventional Results available

Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia

NCT00833547
View directory record Official record
Conditions
Schizophrenia
Interventions
eszopiclone, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 14, 2026, 5:54 PM EDT
Completed Phase 2Phase 3 Interventional

Adjunctive Treatment for Decreasing Symptoms of Schizophrenia

NCT00222235
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
d-cycloserine, glycine, placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 54 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Glen Oaks, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 14, 2026, 5:54 PM EDT
Withdrawn Phase 4 Interventional

Treating Schizophrenic Smokers: Effects on Craving, Cues and Withdrawal

NCT00781755
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
varenicline, Adaptation of Motivational Interviewing
Drug · Behavioral
Lead sponsor
VA Boston Healthcare System
Federal
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Brockton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 14, 2026, 5:54 PM EDT
Completed Not applicable Interventional

Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)

NCT00012558
View directory record Official record
Conditions
Bipolar Disorder
Interventions
lithium, valproate, bupropion, paroxetine, lamotrigine, risperidone, inositol, tranylcypromine, Cognitive Behavioral Therapy, Family-focused Therapy, Interpersonal and Social Rhythms Therapy
Drug · Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
15 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
11
States / cities
Stanford, California • Denver, Colorado • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated May 4, 2007 · Synced Oct 14, 2026, 5:54 PM EDT
Completed Not applicable Interventional

Comparing Thinking Skills for Work (TSW)Home Practice Program With Traditional TSW Program

NCT03005574
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression
Interventions
TSW-HP, TSW-T
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 14, 2026, 5:54 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

NCT05443724
View directory record Official record
Conditions
Schizophrenia
Interventions
Emraclidine 30 mg
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
62
States / cities
Phoenix, Arizona • Bryant, Arkansas • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 14, 2026, 5:54 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

NCT02431702
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Aripiprazole, Haloperidol, Olanzapine, Oral Paliperidone ER, Perphenazine, Quetiapine, Oral Risperidone, Paliperidone Palmitate Injection (PP1M), Paliperidone Palmitate Injection (PP3M)
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 35 Years
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
34
States / cities
Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 14, 2026, 5:54 PM EDT
Completed Phase 3 Interventional

Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia

NCT00086593
View directory record Official record
Conditions
Schizophrenia
Interventions
lamotrigine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
21
States / cities
Little Rock, Arkansas • Garden Grove, California • Glendale, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 14, 2026, 5:54 PM EDT
Completed Phase 4 Interventional Results available

Once-Daily Asenapine for Schizophrenia

NCT01549041
View directory record Official record
Conditions
Schizophrenia
Interventions
Asenapine 10 mg daily in the evening, Asenapine 5 mg twice daily
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Butner, North Carolina
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 14, 2026, 5:54 PM EDT
Not yet recruiting Not applicable Interventional

Mobile Thinking Intervention: A Inital Test

NCT06909422
View directory record Official record
Conditions
Schizophrenia, Clinical High Risk for Psychosis (CHR)
Interventions
Mobile Intervention for Biased Thinking
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 14, 2026, 5:54 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)

NCT04624243
View directory record Official record
Conditions
Schizophrenia
Interventions
Elpipodect, Risperidone, Placebo to MK-8189, Placebo to risperidone
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
35
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 14, 2026, 5:54 PM EDT
Completed Phase 2 Interventional Results available

Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation

NCT00167310
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder, Coronary Artery Disease
Interventions
Eicosapentaenoic acid (omega-3 fatty acid), Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 14, 2026, 5:54 PM EDT
Terminated Phase 3 Interventional Results available

Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia

NCT03593213
View directory record Official record
Conditions
Schizophrenia
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 64 Years
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
42
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 14, 2026, 5:54 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Delta-9-THC and Iomazenil in Healthy Humans

NCT00982982
View directory record Official record
Conditions
Schizophrenia, Mental Disorders, Psychotic Disorders
Interventions
THC and Iomazenil, Placebo (control)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 14, 2026, 5:54 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Cannabinoids, Learning, and Memory

NCT02407808
View directory record Official record
Conditions
Cannabis, Psychotic Disorders
Interventions
THC, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 14, 2026, 5:54 PM EDT
Recruiting Not applicable Interventional

White Matter Plasticity in Schizophrenia

NCT06641297
View directory record Official record
Conditions
Schizophrenia Disorders
Interventions
Music video game
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
15 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 14, 2026, 5:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety and Tolerability Study of PF-03463275 in Healthy Male Japanese and Western Subjects

NCT01159626
View directory record Official record
Conditions
Healthy
Interventions
PF-03463275, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2011 · Synced Oct 14, 2026, 5:54 PM EDT
Completed Phase 4 Interventional Results available

Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia

NCT00833976
View directory record Official record
Conditions
High Triglycerides, Hypercholesterolemia, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Lovaza
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 14, 2026, 5:54 PM EDT
Recruiting Not applicable Interventional

Circuitry-Guided Smoking Cessation in Schizophrenia (UH3)

NCT05276050
View directory record Official record
Conditions
Smoking Cessation, Nicotine Addiction, Schizophrenia
Interventions
active F8-coil delivered rTMS, active H-coil delivered rTMS
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
22 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 14, 2026, 5:54 PM EDT
Completed Not applicable Interventional

Cognitive Remediation for Schizophrenia

NCT00295048
View directory record Official record
Conditions
Schizophrenia
Interventions
Computer Assisted Cognitive Remediation (CACR)
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
3
States / cities
Baltimore, Maryland • Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 14, 2026, 5:54 PM EDT